EirGen Pharma prostate cancer product Eir-013 passes Fed and Fasted clinical trial in US

EirGen Pharma are delighted to announce that their oncology molecule "Eir-013" for prostate cancer has successfully completed fed and fasted clinical studies in August 2008. This is EirGen`s first US clinical trial and adds to the growing success of EirGen`s oncology portfolio.

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.